Charles Barkley is going on the offense after seeing his weight rebound. | Charles Barkley is going on the offense after ...

Despite formidable competition in the growing transthyretin amyloid cardiomyopathy (ATTR-CM) market, a strong early launch ...

AstraZeneca has come up short in another phase 3 trial of the AKT inhibitor Truqap, raising more questions about the ...

Over the years, a host of large drugmakers have inked settlements with the federal authorities to resolve allegations that ...

Once again, several members of Congress have come together to call for an end to the tax deductions that drugmakers receive ...

Novo Nordisk appears to be letting compounded GLP-1 bygones be bygones—at least, in one respect. | Novo Nordisk appears to be ...

Novartis has a lot cooking with new drug launches, and the company is not letting potential U.S. tariffs on pharmaceuticals ...

After consecutive setbacks at the FDA, Regeneron's string of recent troubles with its Eylea franchise is continuing to pull ...

Pfizer is raising the bar for its sweeping cost-savings drive yet again, this time cranking up the total target to $7.7 ...

Merck is particularly exposed to the tariff threat, as much of its production of Keytruda takes place at facilities in ...